Published in J Clin Microbiol on November 20, 2013
Papillomaviruses: Viral evolution, cancer and evolutionary medicine. Evol Med Public Health (2015) 1.13
Human Papillomavirus 16, 18, 31 and 45 viral load, integration and methylation status stratified by cervical disease stage. BMC Cancer (2014) 0.89
Comparison of analytical and clinical performance of CLART HPV2 genotyping assay to Linear Array and Hybrid Capture 2: a split-sample study. BMC Cancer (2015) 0.84
Invited commentary: multiple human papillomavirus infections and type replacement-anticipating the future after human papillomavirus vaccination. Am J Epidemiol (2014) 0.83
Characterization of Intra-Type Variants of Oncogenic Human Papillomaviruses by Next-Generation Deep Sequencing of the E6/E7 Region. Viruses (2016) 0.82
Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study. BMC Cancer (2016) 0.81
Development of a novel liquid bead array human papillomavirus genotyping assay (PGMY-LX) and comparison with linear array for continuity in longitudinal cohort studies. J Clin Microbiol (2015) 0.79
Differential Detection of Human Papillomavirus Genotypes and Cervical Intraepithelial Neoplasia by Four Commercial Assays. J Clin Microbiol (2016) 0.77
HPV Genotyping of Modified General Primer-Amplicons Is More Analytically Sensitive and Specific by Sequencing than by Hybridization. PLoS One (2017) 0.75
Human papillomavirus type 16 long control region and E6 variants stratified by cervical disease stage. Infect Genet Evol (2014) 0.75
Comparison of methods using paraffin-embedded tissues and exfoliated cervical cells to evaluate human papillomavirus genotype attribution. Cancer Sci (2016) 0.75
Genotyping for Human Papillomavirus (HPV) 16/18/52/58 Has a Higher Performance than HPV16/18 Genotyping in Triaging Women with Positive High-risk HPV Test in Northern Thailand. PLoS One (2016) 0.75
Quality assurance of human papillomavirus (HPV) testing in the implementation of HPV primary screening in Norway: an inter-laboratory reproducibility study. BMC Infect Dis (2016) 0.75
HPV-Testing in Follow-up of Patients Treated for CIN2+ Lesions. J Cancer (2016) 0.75
Multiple HPV genotype infection impact on invasive cervical cancer presentation and survival. PLoS One (2017) 0.75
Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer (2007) 10.29
Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol (1998) 9.43
Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol (1999) 6.45
Worldwide burden of cervical cancer in 2008. Ann Oncol (2011) 5.66
GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol (2002) 5.63
Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis (1994) 4.89
Human papillomavirus and cervical cancer. Clin Microbiol Rev (2003) 3.90
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol (1995) 3.20
Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol (2006) 3.13
Detection and typing of human papillomavirus by e6 nested multiplex PCR. J Clin Microbiol (2004) 2.34
Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol (2008) 1.90
Comparison of the performance of different HPV genotyping methods for detecting genital HPV types. J Med Virol (2008) 1.85
Global proficiency study of human papillomavirus genotyping. J Clin Microbiol (2010) 1.78
Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer (2013) 1.68
Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology. Int J Cancer (2006) 1.56
RespiFinder: a new multiparameter test to differentially identify fifteen respiratory viruses. J Clin Microbiol (2008) 1.49
Characterization of a novel human papillomavirus DNA in the cervical carcinoma cell line ME180. J Virol (1991) 1.42
Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus. J Clin Microbiol (2009) 1.40
WHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24-25 January 2008, Geneva, Switzerland. Vaccine (2008) 1.28
Two novel genital human papillomavirus (HPV) types, HPV68 and HPV70, related to the potentially oncogenic HPV39. J Clin Microbiol (1996) 1.26
The 2010 global proficiency study of human papillomavirus genotyping in vaccinology. J Clin Microbiol (2012) 1.24
Confirmatory real-time PCR assay for human papillomavirus (HPV) type 52 infection in anogenital specimens screened for HPV infection with the linear array HPV genotyping test. J Clin Microbiol (2007) 1.20
Development and validation of a real-time PCR assay specifically detecting human papillomavirus 52 using the Roche LightCycler 480 system. J Virol Methods (2007) 1.19
Communication: papillomavirus DNA in basal cell carcinomas of immunocompetent patients: an accidental association?TITLE. J Invest Dermatol (2000) 1.16
Genotyping of human papillomaviruses by a novel one-step typing method with multiplex PCR and clinical applications. J Clin Microbiol (2008) 1.11
Validation of a low-cost human papillomavirus genotyping assay based on PGMY PCR and reverse blotting hybridization with reusable membranes. J Clin Microbiol (2011) 1.09
Performance of commercial reverse line blot assays for human papillomavirus genotyping. J Clin Microbiol (2012) 1.01
Development and evaluation of a liquid bead microarray assay for genotyping genital human papillomaviruses. J Clin Microbiol (2009) 1.00
Real-time Taqman PCR targeting 14 human papilloma virus types. J Clin Virol (2007) 0.98
Establishment of the 1st World Health Organization international standards for human papillomavirus type 16 DNA and type 18 DNA. Int J Cancer (2010) 0.96
First WHO International Reference Panel containing hepatitis B virus genotypes A-G for assays of the viral DNA. J Clin Virol (2012) 0.95
Collaborative study to establish a World Health Organization International genotype panel for parvovirus B19 DNA nucleic acid amplification technology (NAT)-based assays. Vox Sang (2011) 0.91
Development and evaluation of a colorimetric PCR system for the detection and typing of human papillomaviruses. Int J Mol Med (2006) 0.91
Universal ProbeLibrary based real-time PCR assay for detection and confirmation of human papillomavirus genotype 52 infections. J Virol Methods (2009) 0.89
Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med (2007) 5.57
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine (2008) 4.82
Should donors be allowed to give broad consent to future biobank research? Lancet Oncol (2006) 4.30
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer (2004) 4.10
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst (2008) 3.24
Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst (2004) 3.20
Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine (2006) 3.15
Ethical framework for previously collected biobank samples. Nat Biotechnol (2007) 2.81
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Seroepidemiology of the human polyomaviruses. J Gen Virol (2003) 2.32
Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst (2009) 2.32
Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ (2014) 2.27
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst (2013) 1.99
Screening and cervical cancer cure: population based cohort study. BMJ (2012) 1.99
Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect (2011) 1.78
Global proficiency study of human papillomavirus genotyping. J Clin Microbiol (2010) 1.78
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66
Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks. Am J Epidemiol (2008) 1.62
Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients. Gynecol Oncol (2002) 1.56
Cutaneous human papillomaviruses found in sun-exposed skin: Beta-papillomavirus species 2 predominates in squamous cell carcinoma. J Infect Dis (2007) 1.54
Cutaneous human papillomaviruses persist on healthy skin. J Invest Dermatol (2006) 1.53
Nordic biological specimen banks as basis for studies of cancer causes and control--more than 2 million sample donors, 25 million person years and 100,000 prospective cancers. Acta Oncol (2007) 1.51
Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J Cell Mol Med (2009) 1.48
High prevalence of cutaneous human papillomavirus DNA on the top of skin tumors but not in "Stripped" biopsies from the same tumors. J Invest Dermatol (2004) 1.48
Epidemiology of Kaposi's Sarcoma herpesvirus (HHV8) in Västerbotten County, Sweden. J Med Virol (2006) 1.47
Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with human papillomavirus infection. Int J Cancer (2002) 1.47
A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology (2013) 1.44
A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int J Cancer (2002) 1.43
Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus. J Clin Microbiol (2009) 1.40
Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer (2005) 1.39
[In Process Citation]. Lakartidningen (2015) 1.38
Development of a sensitive and specific multiplex PCR method combined with DNA microarray primer extension to detect Betapapillomavirus types. J Clin Microbiol (2007) 1.36
Metagenomic sequencing of "HPV-negative" condylomas detects novel putative HPV types. Virology (2013) 1.27
Assessing quality and functionality of DNA from fresh and archival dried blood spots and recommendations for quality control guidelines. Clin Chem (2007) 1.26
The 2010 global proficiency study of human papillomavirus genotyping in vaccinology. J Clin Microbiol (2012) 1.24
A prospective pilot study of antibodies against human papillomaviruses and cutaneous squamous cell carcinoma nested in the Oxford component of the European Prospective Investigation into Cancer and Nutrition. Int J Cancer (2007) 1.22
Multiple-primer DNA sequencing method. Electrophoresis (2003) 1.21
Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol (2003) 1.20
Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstet Gynecol (2005) 1.18
Type-specific multiple sequencing primers: a novel strategy for reliable and rapid genotyping of human papillomaviruses by pyrosequencing technology. J Mol Diagn (2005) 1.18
Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine (2012) 1.17
Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested case-control study. J Gen Virol (2007) 1.16
High throughput sequencing reveals diversity of Human Papillomaviruses in cutaneous lesions. Int J Cancer (2011) 1.16
Sentinel-base DNA genotyping using multiple sequencing primers for high-risk human papillomaviruses. Mol Cell Probes (2006) 1.15
Heparan sulfate proteoglycans interact exclusively with conformationally intact HPV L1 assemblies: basis for a virus-like particle ELISA. J Med Virol (2005) 1.15
Prevalence and stability of human serum antibodies to simian virus 40 VP1 virus-like particles. J Gen Virol (2005) 1.15
Population-based type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish women. J Med Virol (2002) 1.13
Are 20 human papillomavirus types causing cervical cancer? J Pathol (2014) 1.12
Seroreactivity to cutaneous human papillomaviruses among patients with nonmelanoma skin cancer or benign skin lesions. Cancer Epidemiol Biomarkers Prev (2008) 1.12
High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer (2004) 1.12
Patients would benefit from simplified ethical review and consent procedure. Lancet Oncol (2013) 1.11
Articular cartilage regeneration with autologous marrow aspirate and hyaluronic Acid: an experimental study in a goat model. Arthroscopy (2009) 1.11
Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol (2013) 1.11
Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later. Am J Obstet Gynecol (2003) 1.09
Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am J Epidemiol (2013) 1.09
Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses. Int J Cancer (2006) 1.09
Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine (2006) 1.08
No serological evidence of association between prostate cancer and infection with herpes simplex virus type 2 or human herpesvirus type 8: a nested case-control study. J Infect Dis (2005) 1.08
Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J Clin Virol (2007) 1.06
Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers. Int J Cancer (2008) 1.05
Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.05
Serological diagnosis of human polyomavirus infection. Adv Exp Med Biol (2006) 1.05
Prospective study of human papillomavirus seropositivity and risk of nonmelanoma skin cancer. Am J Epidemiol (2012) 1.04
A candidate CpG SNP approach identifies a breast cancer associated ESR1-SNP. Int J Cancer (2011) 1.03
Population-based study of screening test performance indices of three human papillomavirus DNA tests. J Med Virol (2007) 1.03
Next generation sequencing for human papillomavirus genotyping. J Clin Virol (2013) 1.03
Human papillomavirus typing in reporting of condyloma. Sex Transm Dis (2013) 1.02
Detection of genomic amplification of the human telomerase gene TERC, a potential marker for triage of women with HPV-positive, abnormal Pap smears. Am J Pathol (2009) 1.02
Predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer. Clin Cancer Res (2004) 1.02
Genetic predisposition, parity, age at first childbirth and risk for breast cancer. BMC Res Notes (2012) 1.02
Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia. Obstet Gynecol (2002) 1.01
Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom. Cancer (2002) 1.01
Performance of commercial reverse line blot assays for human papillomavirus genotyping. J Clin Microbiol (2012) 1.01
Comparison of archival plasma and formalin-fixed paraffin-embedded tissue for genotyping in hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev (2005) 1.00
High-throughput genotyping of oncogenic human papilloma viruses with MALDI-TOF mass spectrometry. Clin Chem (2007) 1.00
EUROGIN 2008 roadmap on cervical cancer prevention. Int J Cancer (2009) 1.00
Amplification of the telomerase reverse transcriptase (hTERT) gene in cervical carcinomas. Genes Chromosomes Cancer (2002) 1.00
Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women. Int J Oncol (2009) 0.99
Four novel human betapapillomaviruses of species 2 preferentially found in actinic keratosis. J Gen Virol (2008) 0.99
Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervix. Cancer Epidemiol Biomarkers Prev (2010) 0.99
No excess risk for colorectal cancer among subjects seropositive for the JC polyomavirus. Int J Cancer (2007) 0.99